Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Senseonics Holdings (NY: SENS )

0.4807 +0.0447 (+10.25%)
Streaming Delayed Price Updated: 2:26 PM EDT, Apr 30, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Senseonics Holdings

< Previous 1 2 3 4 5 6 7 8 Next >
Senseonics Announces Business Updates
From Senseonics Holdings, Inc.
Via Business Wire
Eversense NOW Remote Monitoring App for Android Users Receives CE Mark in Europe
From Senseonics Holdings, Inc.
Via Business Wire
7 Top-Rated Penny Stocks for a Happier Holiday Season
In this kind of market one of your best bets is to look toward high quality penny stocks to turbocharge your returns. 
Via InvestorPlace
Topics Economy
Exposures Economy
Even Good Penny Stocks Like Senseonics Aren’t Always Profitable
Its latest implanted sensor lasts six months, but SENS stock faces competition from Dexcom, Abbott Labs and potentially one big name in tech. 
Via InvestorPlace
Senseonics Holdings, Inc. Reports Third Quarter 2021 Financial Results
From Senseonics Holdings, Inc.
Via Business Wire
How Bad Are Senseonics Holdings Common Stock's Earnings? | Return On Capital Employed
Benzinga Pro data, Senseonics Holdings, Inc. Common Stock (AMEX:SENS) reported Q2 sales of $3.29 million. Earnings fell to a loss of $15.89 million, resulting in a 31.34%... 
Via Benzinga
Senseonics to Participate in Upcoming November Investor Conferences
From Senseonics Holdings, Inc.
Via Business Wire
7 Penny Stocks That Could Have an Explosive Year-End
While meme trends are on the wane, these seven penny stocks still stand to make turbocharged moves higher in the short-term. 
Via InvestorPlace
Exposures COVID-19
Senseonics Holdings, Inc. Schedules Third Quarter 2021 Earnings Release and Conference Call for November 9, 2021, at 4:30 p.m. Eastern Time
From Senseonics Holdings, Inc.
Via Business Wire
Senseonics Stock Has a Huge Catalyst you Shouldn’t Sleep On
If its its 180-day Eversense diabetes monitoring product gets approval, SENS stock should shift out of neutral. 
Via InvestorPlace
FDA Approval for Senseonics’ Glucose Monitor Could Double the Stock Price
SENS stock should follow a similar trajectory to DexCom, and if it does, it will likely explode in price following FDA approval. 
Via InvestorPlace
Exposures Product Safety
Senseonics Announces Equity Grants To Employees Under Inducement Plan
From Senseonics Holdings, Inc.
Via Business Wire
Senseonics Stock Will Grow With Increased Product Awareness
It has been a long road to commercializing the Eversense platform, but SENS stock holders should be glad to know that progress is being made. 
Via InvestorPlace
18 Stocks Moving in Tuesday's Pre-Market Session
Gainers ReWalk Robotics Ltd. (NASDAQ: RWLK) rose 37% to $1.78 in pre-market trading after declining around 4% on Monday. ReWalk Robotics, last month, reported Q2 sales of $1.44... 
Via Benzinga
Senseonics Ready to Deliver More Than Just Hope?
SENS stock is up 800% in the past 12 months, but a potential FDA approval could give shares a reason to go even higher. 
Via InvestorPlace
Exposures Product Safety
Senseonics Announces a Collaboration with the University Hospitals Accountable Care Organization (UHACO) in Cleveland, Ohio
From Senseonics Holdings, Inc.
Via Business Wire
Senseonics Stock Looks Like It Is Going to Stay Rangebound for a While
It’s a risk to have one company account for much of your revenue. In the case of Senseonics, that’s a good thing for SENS stock. 
Via InvestorPlace
Use Recent Rally to Take Profits in Senseonics
Sensesonics has quite a ways to go before reaching commercial success. 
Via InvestorPlace
Senseonics to Participate in the H.C. Wainwright Global Investment Conference
From Senseonics Holdings, Inc.
Via Business Wire
Why Shares of Senseonics Soared 30.6% in August
The maker of continuous glucose monitoring systems for diabetes treatment is a meme stock with some fundamental support. 
Via The Motley Fool
Senseonic Stock Is Climbing After Bouncing Back From a Disappointing Q2
Despite a mixed Q2 2021 result, bullish sentiment is building for Senseonics. Here’s why SENS stock can run up in the future. 
Via InvestorPlace
There’s a Pullback Coming for Senseonics Stock, So Get Ready To Pounce
Senseonics has massive potential to disrupt the fast-growing CGM market but SENS stock is significantly overvalued at this point. 
Via InvestorPlace
As Senseonics Stock Stays Elevated, Wait Before Buying
Investors bullish on its Eversense catalyst should continue to sit tight for a better entry point with SENS stock 
Via InvestorPlace
Senseonics Can Move Higher, but Competitive Concerns Abound
Going up against blue-chip competitors in a contested arena will be a tough challenge for SENS stock. 
Via InvestorPlace
Benzinga's Top Ratings Upgrades, Downgrades For August 19, 2021
Upgrades According to DA Davidson, the prior rating for PaySign Inc (NASDAQ: 
Via Benzinga
Revenue Acceleration Will Lift Senseonics
Senseonics is ready to launch Eversense CGM systems globally through its partner. Investors buying SENS stock now will get rewarded. 
Via InvestorPlace
The Fundamentals of Senseonics Make No Sense
Some investors probably got rich buying SENS stock when it was cheap and selling it when it skyrocketed. Good for them, but skip it now. 
Via InvestorPlace
SENS Stock: 2 Big Reasons Senseonics Is Squeezing Higher
Today, two key catalysts are driving interest once again in Senseonics and SENS stock as retail investors focus on institutional buying. 
Via InvestorPlace
Senseonics Could Go Higher, Especially if It Nabs FDA Approval
Senseonics looks interesting here, especially with possible FDA approval. SENS stock is worth 24% more at $4, or even $6-plus once its CGM rolls out. 
Via InvestorPlace
Exposures Product Safety
85 Biggest Movers From Yesterday
Gainers Fulcrum Therapeutics, Inc. (NASDAQ: FULC) jumped 125.3% to close at $18.77 on Tuesday after the company announced positive interim results from the Phase 1 trial with FTX... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.